|
CXCR4 antagonist (BL-8040) to enhance antitumor effects by increasing tumor infiltration of antigen-specific effector T-cells. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - BiolineRx; Teva |
Leadership - BiolineRx; Teva |
Stock and Other Ownership Interests - BiolineRx; Teva |
Honoraria - BiolineRx; Teva |
Consulting or Advisory Role - Teva |
Research Funding - BiolineRx (Inst); Teva (Inst) |
Patents, Royalties, Other Intellectual Property - Patents as per policy of Teva Pharmaceuticals no Royalties |
Travel, Accommodations, Expenses - BiolineRx; Teva |
|
|
|
|
Stock and Other Ownership Interests - BiolineRx |
|
Speakers' Bureau - BiolineRx |
Research Funding - BiolineRx (Inst) |
Travel, Accommodations, Expenses - BiolineRx; BiolineRx |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Advaxis |
Honoraria - Cancer Panels; Genentech; INOVA Health System; MedThink |
Consulting or Advisory Role - AstraZeneca/MedImmune; Gilead Sciences; Nektar; PDS |
Research Funding - Advaxis (Inst); Argos Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); CureTech (Inst); MedImmune (Inst); Medivation (Inst); Merck Serono (Inst); Millennium (Inst); Newlink Genetics (Inst); PDS Biotechnology (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Newlink Genetics |